KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Common Equity for 5 consecutive years, with $1.3 billion as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Common Equity fell 13.24% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Sep 2023, down 13.24%, and an annual FY2022 reading of $1.7 billion, up 10.78% over the prior year.
  • Common Equity was $1.3 billion for Q3 2023 at Ginkgo Bioworks Holdings, down from $1.5 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.7 billion in Q4 2022 and bottomed at $355.8 million in Q2 2021.
  • Average Common Equity over 5 years is $1.2 billion, with a median of $1.5 billion recorded in 2022.
  • The sharpest move saw Common Equity surged 341.91% in 2022, then fell 13.24% in 2023.
  • Year by year, Common Equity stood at $501.9 million in 2019, then dropped by 6.34% to $470.1 million in 2020, then surged by 233.45% to $1.6 billion in 2021, then increased by 10.78% to $1.7 billion in 2022, then decreased by 27.85% to $1.3 billion in 2023.
  • Business Quant data shows Common Equity for DNA at $1.3 billion in Q3 2023, $1.5 billion in Q2 2023, and $1.6 billion in Q1 2023.